US 12343380
Expansion of TILs utilizing AKT pathways inhibitors
granted A61KA61K38/2013A61K39/3955
Quick answer
US patent 12343380 (Expansion of TILs utilizing AKT pathways inhibitors) held by Iovance Biotherapeutics, Inc. expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Iovance Biotherapeutics, Inc.
- Grant date
- Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 28
- CPC classes
- A61K, A61K38/2013, A61K39/3955, A61K40/11, A61K40/42